Novartis AG
ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF

Last updated:

Abstract:

Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

Status:
Application
Type:

Utility

Filling date:

23 Oct 2020

Issue date:

16 Sep 2021